Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 970

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Lomustine and Bevacizumab in Progressive Glioblastoma

Open access
Wick, Wolfgang, Gorlia, Thierry, Bendszus, Martin, Taphoorn, Martin, Sahm, Felix, Harting, Inga, Brandes, Alba A., Taal, Walter, Domont, Julien, Idbaih, Ahmed, Campone, Mario, Clement, Paul M., Stupp, Roger, Fabbro, Michel, Le Rhun, Emilie, Dubois, Francois, Weller, Michael, von Deimling, Andreas, Golfinopoulos, Vassilis, Bromberg, Jacoline C., Platten, Michael, Klein, Martin, van den Bent, Martin J.·2017·New England Journal of Medicine

Abstract

BACKGROUND: Bevacizumab is approved for the treatment of patients with progressive glioblastoma on the basis of uncontrolled data. Data from a phase 2 trial suggested that the addition of bevacizumab to lomustine might improve overall survival as compared with monotherapies. We sought to determine whether the combination would result in longer overall survival than lomustine alone among patients at first progression of glioblastoma. METHODS: -methylguanine-DNA methyltransferase (MGMT) was assessed. Health-related quality of life and neurocognitive function were evaluated at baseline and every 12 weeks. The primary end point of the trial was overall survival. RESULTS: A total of 437 patients underwent randomization. The median number of 6-week treatment cycles was three in the combination group and one in the monotherapy group. With 329 overall survival events (75.3%), the combination therapy did not provide a survival advantage; the median overall survival was 9.1 months (95% confidence interval [CI], 8.1 to 10.1) in the combination group and 8.6 months (95% CI, 7.6 to 10.4) in the monotherapy group (hazard ratio for death, 0.95; 95% CI, 0.74 to 1.21; P=0.65). Locally assessed progression-free survival was 2.7 months longer in the combination group than in the monotherapy group: 4.2 months versus 1.5 months (hazard ratio for disease progression or death, 0.49; 95% CI, 0.39 to 0.61; P<0.001). Grade 3 to 5 adverse events occurred in 63.6% of the patients in the combination group and 38.1% of the patients in the monotherapy group. The addition of bevacizumab to lomustine affected neither health-related quality of life nor neurocognitive function. The MGMT status was prognostic. CONCLUSIONS: Despite somewhat prolonged progression-free survival, treatment with lomustine plus bevacizumab did not confer a survival advantage over treatment with lomustine alone in patients with progressive glioblastoma. (Funded by an unrestricted educational grant from F. Hoffmann-La Roche and by the EORTC Cancer Research Fund; EORTC 26101 ClinicalTrials.gov number, NCT01290939 ; Eudra-CT number, 2010-023218-30 .).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa1707358

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 970

Metadata

Authors
Wick, W., Gorlia, T., Bendszus, M., Taphoorn, M., Sahm, F., Harting, I., Brandes, A. A., Taal, W., Domont, J., Idbaih, A., Campone, M., Clement, P. M., Stupp, R., Fabbro, M., Le Rhun, E., Dubois, F., Weller, M., von Deimling, A., Golfinopoulos, V., Bromberg, J. C., Platten, M., Klein, M., & van den Bent, M. J.
Venue
New England Journal of Medicine
Published
2017-11-16
Volume
377
Issue
20
Pages
1954-1963
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2768388636
Cited by
970
References
2
FWCI
37.60
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Lomustine and Bevacizumab in Progressive Glioblastoma. https://app.cochat.ai/papers/10.1056/nejmoa1707358
The paper
Wick, W., Gorlia, T., Bendszus, M., Taphoorn, M., Sahm, F., Harting, I., Brandes, A. A., Taal, W., Domont, J., Idbaih, A., Campone, M., Clement, P. M., Stupp, R., Fabbro, M., Le Rhun, E., Dubois, F., Weller, M., von Deimling, A., Golfinopoulos, V., . . . van den Bent, M. J. (2017). Lomustine and Bevacizumab in Progressive Glioblastoma. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1707358

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.